Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PENTIDS 800.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PENTIDS 800.
LAROTID vs PENTIDS '800'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Penicillin G is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), transpeptidases that catalyze the final transpeptidation step of peptidoglycan cross-linking, leading to cell lysis.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
800 mg orally every 6 to 8 hours; maximum 4 g per day.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.5-1 hour; prolonged to 2-5 hours in renal impairment.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal: ~60-85% unchanged via glomerular filtration and tubular secretion; Biliary: ~10%; Fecal: <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic